A new research paper was published in Oncotarget's Volume 14 on May 26, 2023, entitled, "Deconstructing the role of MALAT1 in MAPK-signaling in melanoma: insights from antisense oligonucleotide ...
Researchers have proposed a personalised, multi-target therapeutic approach to treat sepsis by dynamically regulating key ...
PAS-004 is being tested in a phase 1 trial for MAPK pathway-driven advanced solid tumors, with dosing initiated at 30 mg. The trial is multicenter, open-label, and dose-escalation, assessing safety, ...
Psoriasis is characterized by hyperproliferation of keratinocytes and increased expression of integrins, but the pathological signaling pathway remains unknown. In August 15 Journal of Clinical ...
Pasithea Therapeutics Corp. has announced the successful enrollment and initial dosing of three subjects in Cohort 6 of its Phase 1 clinical trial for PAS-004, a candidate for treating ...
Erasca, Inc. presents promising preclinical data on ERAS-0015 and ERAS-4001 targeting RAS/MAPK pathway cancers at AACR meeting. Erasca, Inc. presented new preclinical data at the American Association ...
The research conducted by Professor Zou Zui and his team focuses on the immunoregulatory mechanisms in sepsis. As a ...
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced business updates and reported ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback